Literature DB >> 25752202

Circulation of a multiresistant, conjugative, IncA/C plasmid within the nosocomial Providencia stuartii population in the Athens area.

Panagiota Giakkoupi1, Kyriaki Tryfinopoulou2, Michalis Polemis2, Olga Pappa2, Vivi Miriagou3, Alkiviadis Vatopoulos4.   

Abstract

The objective of the study is to report a multidrug-resistant outbreak of Providencia stuartii that occurred in inpatients in the Athens area in 2012 resulting from a very successful transmissible A/C multidrug-resistant plasmid. Thirteen multidrug-resistant P. stuartii clinical isolates from 5 hospitals were studied. Molecular typing was performed by pulsed-field gel electrophoresis. Antibiotic resistance genes and their genetic surround were detected by PCR and sequencing. Plasmid analysis included conjugation experiments using liquid cultures, sizing by S1 digestion, and incompatibility replicon typing by PCR. Isolates were grouped into 2 distinct clonal types A and B, exhibiting similarity less than 70%. Isolates of type A were recovered from patients hospitalized in 4 different hospitals with no obvious epidemiological linkage, while isolates of type B were recovered from patients treated in a single hospital. Both clonal types harbored a conjugative plasmid of 130 bp and IncA/C replicon type carrying 5 β-lactamase genes bla(SHV-5), bla(VEB-1), bla(VIM-1), bla(OXA-10), and bla(TEM-1) and aminoglycosides resistant determinants. All β-lactamase genes were included in stable structures as IS26, IS1999, and In-e541. The current plasmid seemed to have many common determinants with previously reported plasmids derived from P. stuartii and Proteus mirabilis clinical isolates and exhibited the ability to circulate in nosocomial bacterial populations.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Multidrug resistance; Providencia stuartii; SHV-5; VEB-1; VIM-1

Mesh:

Year:  2015        PMID: 25752202     DOI: 10.1016/j.diagmicrobio.2015.02.009

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  6 in total

1.  Characterization of the First OXA-10 Natural Variant with Increased Carbapenemase Activity.

Authors:  Stathis D Kotsakis; Carl-Fredrik Flach; Mohammad Razavi; D G Joakim Larsson
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

2.  Characterization of 16S rRNA methylase genes in Enterobacterales and Pseudomonas aeruginosa in Athens Metropolitan area, 2015-2016.

Authors:  Konstantina Nafplioti; Maria Souli; Panagiota Adamou; Eleni Moraitou; Panagiota Giannopoulou; Paraskevi Chra; Maria Damala; Evangelos Vogiatzakis; Eleftheria Trikka-Graphakos; Vasiliki Baka; Eleni Prifti; Anastasia Antoniadou; Irene Galani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-08-14       Impact factor: 3.267

Review 3.  A Review of SHV Extended-Spectrum β-Lactamases: Neglected Yet Ubiquitous.

Authors:  Apostolos Liakopoulos; Dik Mevius; Daniela Ceccarelli
Journal:  Front Microbiol       Date:  2016-09-05       Impact factor: 5.640

4.  Providencia in retail meats from Guangzhou, China and Osaka, Japan: prevalence, antimicrobial resistance and characterization of classes 1, 2 and 3 integrons.

Authors:  Huiling DI; Sisi Liang; Qingyang Li; Lei Shi; Ayaka Shima; Hecheng Meng; He Yan; Shinji Yamasaki
Journal:  J Vet Med Sci       Date:  2018-03-19       Impact factor: 1.267

5.  Detection in two hospitals of transferable ceftazidime-avibactam resistance in Klebsiella pneumoniae due to a novel VEB β-lactamase variant with a Lys234Arg substitution, Greece, 2019.

Authors:  E Voulgari; S D Kotsakis; P Giannopoulou; E Perivolioti; L S Tzouvelekis; V Miriagou
Journal:  Euro Surveill       Date:  2020-01

6.  Comparative Genomic Analysis Reveals Genetic Mechanisms of the Variety of Pathogenicity, Antibiotic Resistance, and Environmental Adaptation of Providencia Genus.

Authors:  Chao Yuan; Yi Wei; Si Zhang; Juan Cheng; Xiaolei Cheng; Chengqian Qian; Yuhui Wang; Yang Zhang; Zhiqiu Yin; Hong Chen
Journal:  Front Microbiol       Date:  2020-10-27       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.